RxDoctor Payments Data

John Vizuete, MD

Gastroenterology · San Antonio, TXNPI 1477812121

Payments from drug & device makers

$12,178in general payments, 2019–2025

Across 689 payments — averaging $17.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
  • Johnson & Johnson$1K
  • Takeda Pharmaceuticals U.S.A., Inc.$817
  • Pfizer$774
  • Bristol Myers Squibb$473
  • plus $4K from 33 others

What the payments were for

  • Food & beverage$12,140100%
  • Education$380%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,178 in reported general payments places this provider in the 75th percentile of 1,350 gastroenterology providers in Texas.

See all gastroenterology providers in Texas

Medicare billing

Part B allowed, 2024
$108,946
Medicare patients
160
Services billed
3,549

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Mesalamine28$9,942
LinzessLinaclotide13$7,333
Dexlansoprazole DrDexlansoprazole12$6,290
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates53$3,273
ClenpiqSod Picosulf/Mag Ox/Citric Ac14$2,366
Pantoprazole Sodium135$1,557
Budesonide DrBudesonide12$1,034
Colestipol Hcl17$931
CholestyramineCholestyramine (With Sugar)12$540
Dicyclomine Hcl37$429
Ondansetron OdtOndansetron25$408
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl22$342
Omeprazole14$281

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$3,013$7,33313 claims
Ferring Pharmaceuticals Inc.Clenpiq$25$2,36614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,350 gastroenterology providers in Texas.

Other gastroenterology in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →